• Skip to main content

CentreForMedicalHumanities.org

  • Welcome to Centre For Medical Humanities
  • Telehealth Analysis
  • Research Translations
  • Evidence Reviews
  • Blog
  • About Centre For Medical Humanities

Our Battle for Breath: making lung health a priority (Reblog, Ian Jarrold, British Lung Foundation)

posted on August 25, 2026

By CentreForMedicalHumanities.org Research Team | Last verified: September 2026

Research Summary: Respiratory Health Research & Lung Disease Prioritization

Topic: Lung disease research funding and policy priorities in the UK
Disease Burden: 1 in 5 people currently diagnosed with respiratory disease; prevalence expected to increase with population aging
Key Research Areas: Idiopathic pulmonary fibrosis treatment, pneumonia therapeutics, COPD-related cognitive impairment
Funding Status: Respiratory research consistently underfunded relative to disease burden compared to cancer and cardiovascular research; British Lung Foundation invested £600,000+ in pulmonary fibrosis research with £300,000 additional planned
Evidence Grade: Moderate — respiratory disease research in UK is world-leading with emerging treatments for pulmonary fibrosis showing real momentum
Policy Context: Disparity between research spending and disease impact; recent initiatives like the £5 million government-funded National Mesothelioma Centre signal policy shift
Clinical Significance: Multiple effective treatments now available for idiopathic pulmonary fibrosis; collaborative research networks across UK institutions advancing preventions and interventions

This is the fourth and final blog in a series of responses by Life of Breath to the British Lung Foundation’s Battle for Breath report. Join us today at 12:00GMT on Twitter to discuss the issues #breathreport.

Ian Jarrold, the British Lung Foundation’s Head of Research, considers the future of respiratory health in the UK.

When the British Lung Foundation was first set up by Malcolm Green in 1984, there was a lack of funding and focus on respiratory research. Some 32 years later, respiratory research is still consistently underfunded and the government is not putting a focus on respiratory research, as it has for cancers and cardiovascular disease.

Our report, The Battle for Breath, made it clear that there are more people living with lung conditions than previously thought. Currently, 1 in 5 people are diagnosed and living with a respiratory disease. As diagnosis becomes more effective, and as the population ages, we’re likely to see the numbers of people affected by lung conditions increase further. However, there is a marked disparity in research spending on respiratory disorders compared with other comparable disease areas, both in absolute terms and also, more tellingly, in relation to disease burden.

Despite this, respiratory disease research in the UK is both exciting and world-leading. We are moving forward. By forging new collaborations between government, businesses and charities, we will be able to combine our efforts to support game-changing research that will pioneer new interventions to improve outcomes for people with respiratory disease With initiatives like the National Mesothelioma Centre, pump primed with a £5million government grant, there are signs that we are now beginning to move forwards. We want this progress to continue. Our hope is that greater awareness will focus more attention on the need for research to improve daily life and life-expectancy for people living with a lung condition.

One exciting recent development is in the treatment of idiopathic pulmonary fibrosis. Over the last few years, more and more research into pulmonary fibrosis has been happening. Several treatments are now available and there’s real momentum building. There are a number of research groups across the UK who are focusing on this area and working together to make progress, using their improved understanding of pulmonary fibrosis to develop new treatments and preventions. In recent years here at the British Lung Foundation, we’ve spent more than £600,000 on pulmonary fibrosis research. I’m looking forward to giving the go-ahead to invest another £300,000 more on vital research over the coming year. And I can’t wait to see the real-world impact that research has on people with pulmonary fibrosis. Other exciting research projects include a study on the treatment of pneumonia from University Hospital Birmingham and University of Bristol researcher investigating cognitive impairment in people with COPD. We expect results from these studies in January 2017.

The Battle for Breath report laid out the epidemiological landscape – the most complete picture of the respiratory health of the nation in 10 years. This is just the beginning; we are now looking to understand the impact of lung disease, in terms of health economics and related measures. What are the real costs to people living with these conditions, to healthcare systems and to society? And importantly, what approaches could we take to reduce this burden in the coming years. Understanding this will build on the Battle for Breath report and bring additional focus to the urgent need for more research into improving and eventually curing lung conditions. This truly is our battle for breath.

Reference: Snell N, Jarrold I & Holgate S. (2015) ‘The current state of respiratory research in the UK’, Thorax 70(11):0-3

This is the fourth in a series of responses to the British Lung Foundation’s Battle for Breath report. Join us on Twitter to discuss the issues, Thursday 24 November 2016, 12:00GMT#breathreport.

Read the other blogs in this series

Related Articles

  • Nootropic Supplement Safety Guide 2026: Who Should Be Cautio…
  • Nootropic Ingredients Research 2026: What Studies Actually S…
  • How Cognitive Function Changes With Age: 2026 Overview
  • Empathy and memory in theology and literature! (Affiliates’…

This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Filed Under: Reblog, Thought Piece

  • About
  • Editorial Policy
  • Privacy Policy
  • Terms of Service
  • Medical Disclaimer
  • Affiliate Disclosure
  • Contact

CentreForMedicalHumanities.org is an independent health evidence publication. This site is not a medical practice, healthcare provider, academic institution, or research organization. Nothing on this site constitutes medical advice. Consult a qualified healthcare provider before making decisions about supplements, medications, or health interventions. This website is not affiliated with Durham University, the Institute for Medical Humanities, or any academic or medical institution. The domain name reflects previous ownership history and does not indicate institutional affiliation, academic authority, or endorsement. The Durham Institute for Medical Humanities is an active research institute at Durham University — visit their official page for information about their programs and research. Some content on this site contains affiliate links. Purchases made through these links may generate a commission for this publication at no cost to the reader. See our Evidence Standards page for full disclosure details. Content produced by the CMH Evidence Review editorial team. © 2026 CentreForMedicalHumanities.org. All rights reserved. | About | Our Evidence Standards | Non-Affiliation Notice | Privacy Policy